终末期肾病患者无症状颈动脉干预仍可能合理
多中心回顾性队列研究利用TriNetX数据库,比较终末期肾病(ESRD)与非ESRD无症状颈动脉疾病患者接受颈动脉内膜剥脱术(CEA)或颈动脉支架置入术(CAS)后的卒中和死亡结局。ESRD患者长期死亡率近2倍于非ESRD患者,但30天结局及长期卒中率相近,提示对合并症较少的ESRD患者干预仍属合理选择。
要点
- ESRD患者颈动脉干预后3年卒中率15.8% vs 10.0%,死亡风险显著升高。
- ESRD患者5年死亡率32.2%,非ESRD为15.5%,OR 2.59。
- ESRD患者中CEA与CAS的长期卒中和死亡无显著差异。
核心结论
- ESRD患者颈动脉干预后长期死亡率近2倍于非ESRD患者,但神经结局相近。
- 对经过选择的ESRD患者,尤其合并症负担较低者,颈动脉干预仍属合理选择。
研究设计与样本
- 多中心回顾性队列研究,利用TriNetX美国协作网络数据库。
- 纳入2014年1月至2024年8月因无症状颈动脉疾病接受CEA或CAS的ESRD与非ESRD患者。
- 基于术前协变量进行1:1倾向性评分匹配,比较30天、3年和5年卒中和全因死亡率。
主要发现
- 共识别332例ESRD患者和28369例非ESRD患者,匹配后每组329例;男性53.0%,平均年龄67.3±8.7岁,平均随访958天。
- 30天卒中和死亡率两组相当。
- 3年时ESRD组卒中率更高(15.8% vs 10.0%;OR 1.65;95%CI 1.05-2.61)。
- 3年死亡率ESRD组显著更高(23.5% vs 11.8%;OR 2.31;95%CI 1.51-3.53)。
- 5年死亡率ESRD组显著更高(32.2% vs 15.5%;OR 2.59;95%CI 1.78-3.78)。
关键数值与推荐
- ESRD组3年卒中率15.8%,非ESRD组10.0%,OR 1.65(95%CI 1.05-2.61)。
- ESRD组3年死亡率23.5%,非ESRD组11.8%,OR 2.31(95%CI 1.51-3.53)。
- ESRD组5年死亡率32.2%,非ESRD组15.5%,OR 2.59(95%CI 1.78-3.78)。
- ESRD患者中CEA与CAS的5年卒中率19.4% vs 14.0%(P=0.33),5年死亡率33.3% vs 30.1%(P=0.64)。
临床怎么用
- 对ESRD合并无症状颈动脉疾病患者,干预前应充分评估合并症负担和预期寿命。
- 合并症负担较低的ESRD患者仍可考虑CEA或CAS,但需告知长期死亡风险较高。
局限性
- 回顾性观察性设计,可能存在残余混杂。
- ESRD组样本量较小,匹配后每组329例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While carotid endarterectomy (CEA) and carotid artery stenting (CAS) reduce the long-term risk of stroke, patients with a short life expectancy or multiple medical comorbidities, including end-stage renal disease (ESRD), may not derive significant benefit from these interventions. The benefits of intervention are especially questionable for patients with asymptomatic carotid artery disease. We assessed the outcomes of stroke and mortality following carotid intervention in a real-world ESRD population. METHODS: This multicenter retrospective cohort study utilized the TriNetX US Collaborative Network, a global federated database, to identify individuals with and without ESRD who underwent CEA or CAS for asymptomatic carotid artery disease between January 2014 and August 2024. Patients were 1:1 propensity score matched based on preoperative covariates, including demographics, comorbidities, and medications. Thirty-day, 3-year, and 5-year rates of stroke and all-cause mortality were compared between the 2 cohorts, using odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: This study identified 332 ESRD patients and 28,369 non-ESRD patients who underwent carotid intervention for asymptomatic carotid artery disease. Propensity-score matching yielded 329 patients. 53.0% were male with a mean age of 67.3 ± 8.7 years. The mean follow-up was 958 days. Outcomes at 30 days resulted in comparable rates for stroke and mortality. At 3 years, patients with ESRD had greater rates of stroke (15.8% vs. 10.0%; OR, 1.65; 95% CI, 1.05-2.61). Mortality was significantly higher in the ESRD group at both 3 years (23.5% vs. 11.8%; OR, 2.31; 95% CI, 1.51-3.53) and 5 years (32.2% vs. 15.5%; OR, 2.59; 95% CI, 1.78-3.78). Subgroup analysis comparing CEA versus CAS demonstrated similar stroke rates at all time points. Notably, the 5-year stroke rate was 19.4% for CEA versus 14.0% for CAS (P = 0.33). Mortality was comparable at all time points, with 5-year rates of 33.3% for CEA versus 30.1% for CAS (P = 0.64). CONCLUSION: ESRD patients exhibited nearly 2-fold long-term mortality after carotid intervention compared with non-ESRD patients, whereas neurologic outcomes remained comparable. Within ESRD patients, long-term neurologic complications and mortality remained statistically similar. This study highlights the poor prognosis of ESRD patients undergoing carotid intervention. Carotid intervention remains a reasonable option for selected ESRD patients, particularly those with a lower comorbidity burden.
引用
- Tsukagoshi J, Penaloza N, Laico AJ, et al. Carotid Artery Intervention May Still Be Justified in Asymptomatic Patients with End-Stage Renal Disease. Ann Vasc Surg. 2026. PMID: 41887324. doi:10.1016/j.avsg.2026.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。